162 related articles for article (PubMed ID: 9667860)
1. Steroid 5alpha-reductase inhibitors in androgen-dependent disorders.
Harris GS; Kozarich JW
Curr Opin Chem Biol; 1997 Aug; 1(2):254-9. PubMed ID: 9667860
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of steroid 5 alpha-reductase in benign prostatic hyperplasia, male pattern baldness and acne.
Metcalf BW; Levy MA; Holt DA
Trends Pharmacol Sci; 1989 Dec; 10(12):491-5. PubMed ID: 2482561
[TBL] [Abstract][Full Text] [Related]
3. Role of 5α-reductase inhibitors in androgen-stimulated skin disorders.
Azzouni F; Zeitouni N; Mohler J
J Drugs Dermatol; 2013 Feb; 12(2):e30-5. PubMed ID: 23377402
[TBL] [Abstract][Full Text] [Related]
4. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
5. The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders.
Chen W; Zouboulis CC; Orfanos CE
Dermatology; 1996; 193(3):177-84. PubMed ID: 8944337
[TBL] [Abstract][Full Text] [Related]
6. Clinical application of 5alpha-reductase inhibitors.
Cilotti A; Danza G; Serio M
J Endocrinol Invest; 2001 Mar; 24(3):199-203. PubMed ID: 11314752
[TBL] [Abstract][Full Text] [Related]
7. Acne: effect of hormones on pathogenesis and management.
Shaw JC
Am J Clin Dermatol; 2002; 3(8):571-8. PubMed ID: 12358558
[TBL] [Abstract][Full Text] [Related]
8. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
Andriole G; Bruchovsky N; Chung LW; Matsumoto AM; Rittmaster R; Roehrborn C; Russell D; Tindall D
J Urol; 2004 Oct; 172(4 Pt 1):1399-403. PubMed ID: 15371854
[TBL] [Abstract][Full Text] [Related]
9. 5alpha-reductase activity in the prostate.
Steers WD
Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
[TBL] [Abstract][Full Text] [Related]
10. 5α-reductases in human physiology: an unfolding story.
Traish AM
Endocr Pract; 2012; 18(6):965-75. PubMed ID: 23246684
[TBL] [Abstract][Full Text] [Related]
11. Trends in the development of new drugs for treatment of benign prostatic hyperplasia.
Kulig K; Malawska B
Curr Med Chem; 2006; 13(28):3395-416. PubMed ID: 17168713
[TBL] [Abstract][Full Text] [Related]
12. A review on steroidal 5α-reductase inhibitors for treatment of benign prostatic hyperplasia.
Sun J; Xiang H; Yang LL; Chen JB
Curr Med Chem; 2011; 18(23):3576-89. PubMed ID: 21756226
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships for inhibition of human 5alpha-reductases by polyphenols.
Hiipakka RA; Zhang HZ; Dai W; Dai Q; Liao S
Biochem Pharmacol; 2002 Mar; 63(6):1165-76. PubMed ID: 11931850
[TBL] [Abstract][Full Text] [Related]
14. Androgens in women: Hormone-modulating therapies for skin disease.
Azarchi S; Bienenfeld A; Lo Sicco K; Marchbein S; Shapiro J; Nagler AR
J Am Acad Dermatol; 2019 Jun; 80(6):1509-1521. PubMed ID: 30312645
[TBL] [Abstract][Full Text] [Related]
15. Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases.
Salvador JA; Pinto RM; Silvestre SM
J Steroid Biochem Mol Biol; 2013 Sep; 137():199-222. PubMed ID: 23688836
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
[TBL] [Abstract][Full Text] [Related]
17. Prostate diseases--role of sex steroids and their inhibitors.
Welén K; Damber JE
Best Pract Res Clin Endocrinol Metab; 2011 Apr; 25(2):355-67. PubMed ID: 21397203
[TBL] [Abstract][Full Text] [Related]
18. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
Traish AM
Adv Exp Med Biol; 2017; 1043():473-526. PubMed ID: 29224108
[TBL] [Abstract][Full Text] [Related]
19. Steroid 5alpha-reductase inhibitors.
Flores E; Bratoeff E; Cabeza M; Ramirez E; Quiroz A; Heuze I
Mini Rev Med Chem; 2003 May; 3(3):225-37. PubMed ID: 12570838
[TBL] [Abstract][Full Text] [Related]
20. Role of 5α-reductase inhibitors in benign prostatic diseases.
Azzouni F; Mohler J
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):222-30. PubMed ID: 22333687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
